4-cresol metabolic pathway

The 4-cresol metabolic pathway is a microbial process in the human gut where the amino acid tyrosine is converted into 4-cresol (p-cresol) by specific anaerobic bacteria, such as Clostridium difficile (Saito et al., 2018). This pathway involves the intermediate p-hydroxyphenylacetate, which is decarboxylated by the bacterial enzyme p-hydroxyphenylacetate decarboxylase (Selmer & Andrei, 2001). Once synthesized, 4-cresol is absorbed and conjugated in the liver to form p-cresyl sulfate (PCS) and p-cresyl glucuronide (PCG), which are potent uremic toxins (Gryp et al., 2017). In patients with chronic kidney disease, these metabolites accumulate and contribute to systemic inflammation, oxidative stress, and cardiovascular complications (Gryp et al., 2017). Additionally, elevated levels of 4-cresol have been linked to the pathophysiology of autism spectrum disorder, potentially affecting neurodevelopment via the gut-brain axis (Persico & Napolioni, 2013). Therapeutic interventions targeting this pathway include the use of oral adsorbents like AST-120 to sequester 4-cresol and its precursors, as well as probiotics and prebiotics to modulate the gut microbiota and reduce the abundance of p-cresol-producing bacteria (Niwa, 2011).

Other names

p-cresol production pathwayMicrobial tyrosine metabolismp-hydroxyphenylacetate decarboxylation pathwayGut microbial p-cresol biosynthesis

Sequestration of metabolic precursors in the gastrointestinal tract, modulation of the gut microbiome to reduce p-cresol-producing species, and potential inhibition of bacterial enzymes such as p-hydroxyphenylacetate decarboxylase.